Actualités WPD Pharmaceuticals Inc - WBIO | Actions Canadian Securities Exchange

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

VANCOUVER, British Columbia, Oct. 15, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

VANCOUVER, British Columbia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

VANCOUVER, British Columbia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

VANCOUVER, British Columbia, July 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial...

VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE:...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

WPD Pharmaceuticals Inc (WBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

WBIO Actualités

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122

WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

WPD Pharmaceuticals To Resume Trading

WPD Pharmaceuticals Comments on SEC Order

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

WPD Pharmaceuticals Inc (WBIO) Actualités

WPD Pharmaceuticals Inc (WBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

WBIO Actualités

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122

WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

WPD Pharmaceuticals To Resume Trading

WPD Pharmaceuticals Comments on SEC Order

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application